Virtual Library
Start Your Search
Minzhang Guo
Author of
-
+
P2.03 - Biology (ID 162)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Biology
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.03-50 - Stromal BTK Expression Predicts Poor Prognosis in NSCLC Patients (ID 1665)
10:15 - 18:15 | Author(s): Minzhang Guo
- Abstract
Background
Bruton's tyrosine kinase (BTK) is a kinase that plays a crucial role in B-cell development and widely involves cancer biology. We sought to explore the relationship between BTK expression and NSCLC.
Method
We firstly used a cohort of 1,249 consecutive NSCLC patients who underwent surgical resection in our center between Apr 2018 and Sep 2018 with fresh tissue to examine the presence of BTK (cohort 1). Another cohort of 681 patients with resected NSCLC between 2009-2014 with stored paraffin sections and survival information were also retrieved to assess the prognostic value of BTK (cohort 2). All samples were stained by IHC for BTK (EPR20445) and PD-L1 (SP142).
Result
The overall expression rates of BTK expression on tumor and stromal cells were 11.9% and 87.1% respectively in cohort 1, which did not differ across histological types or other clinical features. Both tumoral expression (Chi2=8.84, P<0.01) and stromal expression (Chi2=3.96, P=0.047) of BTK were positively correlated with tumoral PDL1 expression. In cohort 2, we found that the stromal (HR=1.49, P=0.03) but not tumoral (HR=0.74, P=0.20) BTK expression was significantly correlated with poorer prognosis, after adjusting for tumoral PDL1 expression (HR=0.58, P<0.01) and other covariates.
Conclusion
This is the first study showing the presence of BTK expression and its positive correlation with PDL1 expression in NSCLC. Stromal BTK expression predicts poor prognosis in NSCLC patients. This study shed light on the biological effect of BTK-expressing cells and treatment potential of targeting relevant pathways.
